公开(公告)号：US20240336697A1

公开(公告)日：2024-10-10

申请号：US18681787

申请日：2022-08-02

申请人： Genentech, Inc. ,  Hoffmann-La Roche Inc.

发明人： Jamie Harue HIRATA ,  Calvin Ka Yin LEE ,  Huan JIN ,  Lijia WANG ,  Jiaheng QIU ,  Qingxiang YAN

IPC分类号： C07K16/28 ,  A61K9/00 ,  A61K31/573 ,  A61K31/675 ,  A61K31/704 ,  A61K39/00 ,  A61P35/00

CPC分类号： C07K16/2887 ,  A61K9/0019 ,  A61K31/573 ,  A61K31/675 ,  A61K31/704 ,  A61P35/00 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2039/55

摘要： Provided herein are methods of treating B-cell proliferative disorders (such as diffuse large B-cell lymphoma “DLBCL”) using immunoconjugates comprising anti-CD79b antibodies in combination with an anti-CD20 antibody, chemotherapy and a corticosteroid.

公开(公告)号：US20240336674A1

公开(公告)日：2024-10-10

申请号：US18423352

申请日：2024-01-26

申请人： Boehringer Ingelheim International GmbH

发明人： Leo THOMAS ,  Rachel Rebecca BARRETT ,  Kristin Laura BOVAT ,  Rajkumar GANESAN ,  Priyanka GUPTA ,  Fei HAN ,  Dongmei LIU ,  Juergen PRESTLE ,  Sanjaya SINGH ,  Sathyadevi VENKATARAMANI ,  Helen Haixia WU ,  Nina ZIPPEL

IPC分类号： C07K16/18 ,  A61K9/00

CPC分类号： C07K16/18 ,  A61K9/0048 ,  C07K2317/565

摘要： The present invention relates to antibodies and fragments thereof that target semaphorin 3A (Sema3A). More specifically, anti-Sema3A antibodies and methods of use for the treatment of various diseases or disorders are disclosed.

公开(公告)号：US20240335550A1

公开(公告)日：2024-10-10

申请号：US18628261

申请日：2024-04-05

申请人： Sleep Solutions of Texas, LLC

发明人： Raghavendra Vitthalrao GHUGE

IPC分类号： A61K47/64 ,  A61K9/00 ,  A61K9/70 ,  A61K31/165 ,  A61K31/513 ,  A61K31/573 ,  A61K31/58 ,  A61K41/00

CPC分类号： A61K47/6435 ,  A61K9/006 ,  A61K9/7007 ,  A61K31/165 ,  A61K31/513 ,  A61K31/573 ,  A61K31/58 ,  A61K41/0042

摘要： Mucosal patches are disclosed that have a support layer supporting an active layer that has a collagen carbon dot nanocomposite carrying an active agent. The collagen carbon dot nanocomposite is absorbable through a mucosa. The mucosal patches are part of various methods of treatment.

公开(公告)号：US20240335501A1

公开(公告)日：2024-10-10

申请号：US18625923

申请日：2024-04-03

申请人： Tulex Pharmaceuticals Inc.

发明人： Yu-Hsing TU ,  Kalyan KATHALA ,  Romona BHATTACHARYA ,  Yingjun FAN ,  Ashok PERUMAL

IPC分类号： A61K38/095 ,  A61K9/00 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/18

CPC分类号： A61K38/095 ,  A61K9/0053 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/183

摘要： Provided herein are desmopressin oral liquid formulations. Also provided herein are methods of making and using desmopressin oral liquid compositions for the treatment of certain diseases including diabetes insipidus, enuresis, hemophilia A, von willebrand disease, high blood urea levels and others.

公开(公告)号：US20240335460A1

公开(公告)日：2024-10-10

申请号：US18578646

申请日：2022-07-12

申请人： STABICAN B.V.

发明人： Robin DE BRUIJN

IPC分类号： A61K31/00 ,  A61K9/00 ,  A61K9/20 ,  A61K9/50

CPC分类号： A61K31/658 ,  A61K9/0002 ,  A61K9/2081 ,  A61K9/5089

摘要： The invention relates to a process for preparing cannabinoid-containing particles, wherein first a solution is provided wherein the solvent has a water solubility in the range of 2-100 g/L at 25° C. and wherein the solution comprises 1) a cannabinoid component comprising one or more cannabinoids; and 2) a shell-forming component comprising one or more compounds selected from the group of C10-C30 fatty alcohols. C10-C30 fatty acids and esters of C10-C30 fatty alcohols and C10-C30 fatty acids. Then, droplets of the solution are generated in an aqueous medium and the solvent is allowed to migrate from the droplets to the aqueous medium to thereby form solid particles wherein a shell of shell-forming component encapsulates the cannabinoid component.

公开(公告)号：US20240335433A1

公开(公告)日：2024-10-10

申请号：US18627617

申请日：2024-04-05

申请人： Dennis W. Stacey

发明人： Dennis W. Stacey

IPC分类号： A61K31/4375 ,  A61K9/00 ,  A61P35/00

CPC分类号： A61K31/4375 ,  A61K9/0019 ,  A61P35/00

摘要： A normal cell cycle synchronization process includes repeated administration of a drug specifically toxic for a single cell cycle phase to selectively synchronize normal cells. The selective synchronization of normal cells allows for the selective targeting of abnormal cells with cell cycle phase specific toxins. Such selective targeting may be useful in the treatment of a number of medical conditions.

公开(公告)号：US20240335425A1

公开(公告)日：2024-10-10

申请号：US18439468

申请日：2024-02-12

申请人： Allergan, Inc.

发明人： Richard Graham ,  Ke Wu ,  Massoud Fahid ,  Mohammed Dibas

IPC分类号： A61K31/4184 ,  A61K9/00 ,  A61K9/08 ,  A61K47/02 ,  A61K47/12 ,  A61P27/10

CPC分类号： A61K31/4184 ,  A61K9/0048 ,  A61K9/08 ,  A61K47/02 ,  A61K47/12 ,  A61P27/10

摘要： Methods of using the alpha-2-adrenergic receptor agonist of Formula I:




for improving vision such as in the treatment of ocular conditions such as presbyopia, poor night vision, visual glare, visual starbursts, visual halos, and some forms of myopia (e.g. night myopia) are described.

公开(公告)号：US20240335424A1

公开(公告)日：2024-10-10

申请号：US18292797

申请日：2022-07-27

申请人： Raziel Therapeutics Ltd.

发明人： Alon BLOOMENFELD ,  Racheli GUETA ,  Eran BLAUGRUND

IPC分类号： A61K31/403 ,  A61K9/00 ,  A61K9/08 ,  A61K47/10 ,  A61P23/02

CPC分类号： A61K31/403 ,  A61K9/0019 ,  A61K9/08 ,  A61K47/10 ,  A61P23/02

摘要： The invention provides carbazole derivatives for the treatment of lipoma pain in tissues and organs, in particular treatment of lipoma pain in Dercum's Disease (DD) patients.

公开(公告)号：US20240335413A1

公开(公告)日：2024-10-10

申请号：US18295494

申请日：2023-04-04

申请人： Anthony Beretta

发明人： Anthony Beretta

IPC分类号： A61K31/245 ,  A61K9/00 ,  A61K31/045 ,  A61K31/222 ,  A61K33/30 ,  A61K35/64 ,  A61K36/185 ,  A61K36/534 ,  A61K36/54 ,  A61K47/44

CPC分类号： A61K31/245 ,  A61K9/0014 ,  A61K31/045 ,  A61K31/222 ,  A61K33/30 ,  A61K35/64 ,  A61K36/185 ,  A61K36/534 ,  A61K36/54 ,  A61K47/44

摘要： A method for topically reducing pain and stimulating healing, including providing a homogeneous composition including 15 to 20 weight percent benzocaine, 1 to 2 weight percent menthol, 5 to 15 weight percent zinc oxide, to 10 weight percent octinovate, 1 to 5 weight percent peppermint oil, 0 to 10 weight percent cinnamon oil, 0 to 20 weight percent bee venom, 5 to 20 weight percent cocoa butter, with the balance being nonreactive base matrix material, and then topically applying the homogeneous composition to skin where pain reduction and healing is desired.

公开(公告)号：US20240335412A1

公开(公告)日：2024-10-10

申请号：US18257569

申请日：2021-12-17

申请人： VIRBAC

发明人： Aurélie GIRARDIN ,  Patricia MONGINOUX ,  Cécile LE JEANNE ,  Jean JOLIVET

IPC分类号： A61K31/231 ,  A61K9/00 ,  A61K31/23 ,  A61K47/02 ,  A61K47/32 ,  A61P25/22

CPC分类号： A61K31/231 ,  A61K9/007 ,  A61K31/23 ,  A61K47/02 ,  A61K47/32 ,  A61P25/22

摘要： The present invention relates to portable pet devices capable of passively diffusing semiochemical compositions; these soothing devices allow animals to better manage stress-generating situations (situations of separation, withdrawal, transport, fear of noises, fireworks, etc.) and allow them to better adapt to the new situations.